Drug Trial Radar · NCT07748702
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Sep 19, 2026
Primary completion
Oct 7, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-339 in healthy volunteers.
Conditions
- Hypertension
Interventions
CKD-339Drug
QD, PO
D311, D107Drug
QD, PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCt of CKD-339Time frame: From 0 to 72 hours postdose
- Cmax of CKD-339Time frame: From 0 to 72 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bumin Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.